Stemtech Revenue Growth Rates (STEK), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Stemtech Corporation  (STEK)
 

STEK's Revenue Growth by Quarter and Year

Stemtech's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

STEK Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.63
1st Quarter March 0.46
FY 1.09

STEKs Annual Revenue
Stemtech's Revenue in the fiscal year 2025 $ 2.88 millions
Stemtech's Revenue in the fiscal year 2024 $ 4.73 millions
Stemtech's Revenue in the fiscal year 2023 $ 4.92 millions
Stemtech's Revenue in the fiscal year 2022 $ 4.50 millions
Stemtech's Revenue in the fiscal year 2021 $ 5.33 millions




STEK Revenue second quarter 2026 Y/Y Growth Comment
Stemtech Corporation reported fall in Revenue in the second quarter 2026 by -10.1% to $ 0.63 millions, from the same quarter in 2025.
Despite modest results in the second quarter 2026, contraction in Stemtech Corporation's Revenue appears to be smaller than Company's recent average decline.

Looking into second quarter 2026 results within Pharmacy Services & Retail Drugstore industry 8 other companies have achieved higher Revenue growth. While Stemtech Corporation' s Revenue decrease of -10.1% ranks overall at the positon no. 3697 in the second quarter 2026.


STEK Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -64.89 % -4.38 % 234.15 %
3rd Quarter September - -17.48 % -20.77 % 26.21 %
2nd Quarter June -10.1 % -47.37 % 17.7 % -31.93 %
1st Quarter March -47.13 % -36.96 % 23.21 % -20 %
FY   - -42.97 % 2.64 % -

Financial Statements
Stemtech's second quarter 2026 Revenue $ 0.63 millions STEK's Income Statement
Stemtech's second quarter 2025 Revenue $ 0.70 millions Quarterly STEK's Income Statement


STEK Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -45.88 % 27.18 % 5.38 %
3rd Quarter September - 21.43 % -22.56 % 15.04 %
2nd Quarter June 36.81 % -19.54 % -3.62 % 0.89 %
1st Quarter March 0 % -33.59 % 0.73 % 173.17 %
FY (Year on Year)   - -42.97 % 2.64 % -


Back to STEK Growth rate Comparisons >> Back to STEK Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Pharmacy Services & Retail Drugstore Industry #9
Retail Sector #180
Overall #3697

Revenue Y/Y Growth Statistics
High Average Low
46.12 % -14.85 % -56.13 %
(Jun 30 2024)   (Jun 30 2023)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Pharmacy Services & Retail Drugstore Industry #9
Retail Sector #180
Overall #3697
Revenue Y/Y Growth Statistics
High Average Low
46.12 % -14.85 % -56.13 %
(Jun 30 2024)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Stemtech's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
387.38 % 20.87 % -68.3 %
(Dec 31 2021)  


STEK's II. Quarter Q/Q Revenue Comment
Stemtech Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 36.81%, to $ 0.63 millions, from $0.46 millions in the first quarter.
STEK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Pharmacy Services & Retail Drugstore industry Stemtech Corporation achieved highest sequential Revenue growth. While Stemtech's Revenue growth quarter on quarter, overall rank is 485.


Revenue Q/Q Growth Company Ranking
Within: No.
Pharmacy Services & Retail Drugstore Industry #1
Retail Sector #28
Overall #485
Revenue Q/Q Growth Company Ranking
Within: No.
Pharmacy Services & Retail Drugstore Industry #1
Retail Sector #28
Overall #485
Revenue Q/Q Growth Statistics
High Average Low
387.38 % 20.87 % -68.3 %
(Dec 31 2021)  


STEK's II. Quarter Q/Q Revenue Comment
Stemtech Corporation achieved in the II. Quarter 2026 above company average sequential Revenue jump of 36.81%, to $ 0.63 millions, from $0.46 millions in the first quarter.
STEK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Pharmacy Services & Retail Drugstore industry Stemtech Corporation achieved highest sequential Revenue growth. While Stemtech's Revenue growth quarter on quarter, overall rank is 485.


Stemtech's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2.40 $ 2.47 $ 2.88 $ 3.73 $ 3.91
Y / Y Revenue Growth (TTM) -38.57 % -45.56 % -43.08 % -27.03 % -27.32 %
Year on Year Revenue Growth Overall Ranking # 4191 # 575 # 264 # 433 # 1152
Seqeuential Revenue Change (TTM) -2.78 % -14.08 % -22.93 % -4.58 % -13.83 %
Seq. Revenue Growth (TTM) Overall Ranking # 3929 # 2834 # 1396 # 1361 # 476


Cumulative Revenue growth Comment
Stemtech showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Stemtech's annual Revenue fall would be -38.57% year on year to $2 millions.

In the Retail sector 198 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 575 to 4191.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Pharmacy Services & Retail Drugstore Industry # 9
Retail Sector # 199
Overall # 4191

Revenue TTM Y/Y Growth Statistics
High Average Low
46.12 %
 -14.85 %
-56.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 189
S&P 500 # 3929
Cumulative Revenue growth Comment
Stemtech showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Stemtech's annual Revenue drop would be -38.57% year on year to $2 millions.

In the Retail sector 198 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 575 to 4191.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Pharmacy Services & Retail Drugstore Industry # 9
Retail Sector # 199
Overall # 4191

Revenue TTM Y/Y Growth Statistics
High Average Low
46.12 %
-14.85 %
-56.13 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 9
Sector # 189
S&P 500 # 3929




Other Revenue Growth
Pharmacy Services & Retail Drugstore Industry Revenue Growth Trends and Statistics
Retail Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
STEK's Revenue Growth Ratio versus Pharmacy Services & Retail Drugstore Industry, Retail Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Retail SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
A k a Brands Holding Corp -0.28%$ -0.284 millions
Autonation Inc -0.64%$ -0.639 millions
Rush Enterprises Inc -1.61%$ -1.607 millions
Camping World Holdings Inc -2.12%$ -2.121 millions
Live Ventures Inc-3.01%$ -3.007 millions
Onewater Marine Inc -4.01%$ -4.007 millions
Crown Equity Holdings Inc -5.52%$ -5.521 millions
Group 1 Automotive Inc-5.57%$ -5.571 millions
Marinemax Inc -6.91%$ -6.909 millions
Driven Brands Holdings Inc -7.91%$ -7.908 millions
Builders Firstsource Inc -8.77%$ -8.774 millions
Stemtech Corporation-9.83%$ -9.831 millions
Qvc Group Inc -10.64%$ -10.644 millions
The Honest Company Inc -10.87%$ -10.867 millions
Qvc inc -11.04%$ -11.038 millions
1 800 Flowers Com Inc-12.92%$ -12.924 millions
Evgo Inc -15.44%$ -15.437 millions
Grove Collaborative Holdings Inc -15.73%$ -15.730 millions
Lulu s Fashion Lounge Holdings Inc -16.22%$ -16.217 millions
Nu Skin Enterprises Inc -17.01%$ -17.012 millions
Healthy Choice Wellness Corp -17.34%$ -17.337 millions
Latch Inc -18.05%$ -18.053 millions
Petmed Express Inc -18.63%$ -18.626 millions
The Beachbody Company Inc -21.55%$ -21.546 millions
Bark Inc -22.79%$ -22.789 millions
Kingfish Holding Corporation-26.76%$ -26.761 millions
Digital Brands Group Inc -29.41%$ -29.411 millions
Pony Group Inc -29.49%$ -29.489 millions
Weis Markets inc-40.10%$ -40.105 millions
Wellgistics Health Inc -76.29%$ -76.287 millions


About Stemtech Revenue Growth Rates (STEK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Stemtech Corp (CIK 1511820).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001683168-26-006490
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Stemtech Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.